Llewelyn Rao, MD
Retina Specialist · Beachwood, OHNPI 1518165448
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.2%), other and ownership interests — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by US Retina LLC at 42.9% of the total. Reporting peaked in 2021 at $24,950 and has fallen 95.4% since, to $1,140 in 2025.
Across 293 payments — averaging $198.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$25K
- Carl Zeiss Meditec, Inc.$18K
- Genentech USA, Inc.$5K
- Alimera Sciences, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- AbbVie$1K
- plus $3K from 21 others
Across 156 payments — averaging $4231.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$487K
- Regeneron$173K
What the payments were for
- Consulting fees$22,23038%
- Speaking & faculty fees$1,5493%
- Food & beverage$9,57616%
- Ownership interest$11,59420%
- Other$13,30723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 8 | $24,977 |
| Carl Zeiss Meditec, Inc. | 4 | $18,028 |
| Genentech USA, Inc. | 38 | $5,455 |
| Alimera Sciences, Inc. | 33 | $3,318 |
| Regeneron Healthcare Solutions, Inc. | 72 | $1,834 |
| AbbVie(2 entities) | 40 | $1,225 |
| Dutch Ophthalmic, USA | 9 | $990 |
| Apellis Pharmaceuticals, Inc. | 23 | $571 |
| Astellas Pharma US Inc | 11 | $329 |
| Novartis | 14 | $298 |
| Coherus Oncology, Inc. | 5 | $236 |
| Notal Vision, Inc. | 1 | $159 |
| Bausch & Lomb Americas Inc. | 3 | $136 |
| ANI Pharmaceuticals, Inc. | 6 | $113 |
| Eyepoint US, Inc. | 6 | $101 |
| Genentech, Inc. | 1 | $93 |
| Harrow Eye, LLC | 3 | $89 |
| Biogen | 3 | $67 |
| Rayner Intraocular Lenses Limited | 3 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Kala Pharmaceuticals, Inc. | 2 | $27 |
| Ivantis, Inc | 1 | $25 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Alcon | 1 | $17 |
| Omeros Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clarus 700$18,000
- VABYSMO$2,655
- SUSVIMO$2,518
- Iluvien$2,446
- YUTIQ$1,806
- EVA, combined machine$398
- TISSUEBLUE$398
- OZURDEX$363
- EVA Ophthalmic Surgical System$304
- EYLEA$287
- EYLEA HD$278
- Lucentis$138
- Cimerli$135
- XIPERE$100
How this compares
$58,256 in reported general payments places this provider in the 85th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 470 | $12,742 |
| Brimonidine Tartrate | 77 | $3,422 |
| Ketorolac Tromethamine | 147 | $2,404 |
| Ofloxacin | 199 | $1,990 |
| Latanoprost | 247 | $1,711 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 84 | $1,306 |
| Timolol Maleate | 30 | $307 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Beachwood
- Joseph ConeyBeachwood$980K
- David MillerBeachwood$299K
- Michael NovakBeachwood$71K
- Scott PendergastBeachwood$66K
- Jerome SchartmanBeachwood$30K
- Sean PlattBeachwood$23K
- Lediana GoduniBeachwood$9K
- Shawn LewisBeachwood$7K
- David ShiehBeachwood$3K
- Hernando ZegarraBeachwood$478
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.